Janssen seeks Health Canada approval for its COVID-19 vaccine

Regulator currently evaluating data from 4 vaccine makers
Ryan Patrick Jones · CBC News · Posted: Dec 01, 2020 10:45 AM ET | Last Updated: 26 minutes ago

A woman receives an injection during Phase 3 testing for the Janssen Pharmaceutical-Johnson & Johnson vaccine in the U.S. The company has begun the Health Canada approval process, Health Minister Patty Hajdu said on Monday. (Johnson & Johnson/The Associated Press)

A fourth company has submitted its COVID-19 vaccine candidate for Health Canada approval, Health Minister Patty Hajdu said Monday.

Hajdu called the request for vaccine approval by Janssen Inc., a pharmaceutical subsidiary of U.S.-based multinational Johnson & Johnson, “a promising development for Canadians.”

Ottawa announced a deal with Janssen on Aug. 31 to secure up to 38 million doses of the vaccine — which requires only one dose to provide immunity, instead of two.

Janssen’s vaccine is a non-replicating viral vector vaccine — based on viral material that has been genetically engineered so it can’t replicate and cause disease.

Johnson & Johnson began Phase 3 clinical trials in September with a massive study that would test the shot in 60,000 volunteers in the United States, South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru. The trial was put on hold in early October as the company investigated an “unexplained illness” among one of the study’s participants, but was restarted just weeks later after the company reported finding no evidence that the vaccine had caused the volunteer to fall ill.

Health Canada is evaluating three other vaccine candidates as part of what it calls a “rolling review process” that allows companies to submit data from clinical trials even as those trials are still underway.
http://rivista.clamerinforma.it/ucl/cast/A-M-hena01.html
http://rivista.clamerinforma.it/ucl/cast/A-M-hena02.html
http://rivista.clamerinforma.it/ucl/cast/A-M-hena03.html
http://rivista.clamerinforma.it/ucl/cast/A-M-hena04.html
http://rivista.clamerinforma.it/ucl/cast/A-M-hena05.html
https://mrdeals.it/ucl/b-in-hhg6.html
https://mrdeals.it/ucl/b-in-hhg7.html
https://mrdeals.it/ucl/b-in-hhg8.html
https://mrdeals.it/ucl/b-in-hhg9.html
https://mrdeals.it/ucl/b-in-hhg10.html
https://lasallelalaguna.es/ucl/b-in-hhg1.html
https://lasallelalaguna.es/ucl/b-in-hhg2.html
https://lasallelalaguna.es/ucl/b-in-hhg3.html
https://lasallelalaguna.es/ucl/b-in-hhg4.html
https://lasallelalaguna.es/ucl/b-in-hhg5.html
https://www.atca.org/ucl/rexx/b-in-hhg6.html
https://www.atca.org/ucl/rexx/b-in-hhg7.html
https://www.atca.org/ucl/rexx/b-in-hhg8.html
https://www.atca.org/ucl/rexx/b-in-hhg9.html
https://www.atca.org/ucl/rexx/b-in-hhg10.html
https://www.atca.org/ucl/rexx/b-in-hhg11.html
https://www.docukit.nl/UEFA/inter-borus-tvst01.html
https://www.docukit.nl/UEFA/inter-borus-tvst02.html
https://www.docukit.nl/UEFA/inter-borus-tvst03.html
https://www.docukit.nl/UEFA/inter-borus-tvst04.html
http://www.skylineoffices.co.uk/cnn/inter-borus-tvst05.html
http://www.skylineoffices.co.uk/cnn/inter-borus-tvst06.html
http://www.skylineoffices.co.uk/cnn/inter-borus-tvst07.html
http://www.skylineoffices.co.uk/cnn/inter-borus-tvst08.html
https://lasallelalaguna.es/ucl/Re-vs-Sh-spo1.html
https://lasallelalaguna.es/ucl/Re-vs-Sh-spo2.html
https://lasallelalaguna.es/ucl/Re-vs-Sh-spo3.html
https://lasallelalaguna.es/ucl/Re-vs-Sh-spo4.html
https://lasallelalaguna.es/ucl/Re-vs-Sh-spo5.html
http://rivista.clamerinforma.it/ucl/cast/At-Mi-IT01.html
http://rivista.clamerinforma.it/ucl/cast/At-Mi-IT02.html
http://rivista.clamerinforma.it/ucl/cast/At-Mi-IT03.html
https://mrdeals.it/ucl/At-Mi-IT04.html
https://mrdeals.it/ucl/At-Mi-IT05.html
https://mrdeals.it/ucl/At-Mi-IT06.html
https://blog.knife-depot.com/cnn/At-Mi-IT08.html
https://blog.knife-depot.com/cnn/At-Mi-IT09.html
https://blog.knife-depot.com/cnn/Atle-Ma-v-Bay-Mumu01.html
https://blog.knife-depot.com/cnn/Atle-Ma-v-Bay-Mumu02.html
https://blog.knife-depot.com/cnn/Atle-Ma-v-Bay-Mumu03.html
https://blog.knife-depot.com/cnn/Atle-Ma-v-Bay-Mumu04.html
https://lauing.de/RTL/Atle-Ma-v-Bay-Mumu05.html
https://lauing.de/RTL/Atle-Ma-v-Bay-Mumu06.html
https://www.docukit.nl/UEFA/oly-v-mar-01.html
https://www.docukit.nl/UEFA/oly-v-mar-02.html
https://www.docukit.nl/UEFA/oly-v-mar-03.html
https://www.docukit.nl/UEFA/oly-v-mar-04.html
https://www.docukit.nl/UEFA/oly-v-mar-05.html
https://www.docukit.nl/UEFA/oly-v-mar-06.html
https://www.docukit.nl/UEFA/oly-v-mar-07.html
https://www.docukit.nl/UEFA/oly-v-mar-08.html
https://www.docukit.nl/UEFA/oly-v-mar-09.html
https://lasallelalaguna.es/ucl/oly-v-mar-01.html
https://lasallelalaguna.es/ucl/oly-v-mar-02.html
https://lasallelalaguna.es/ucl/oly-v-mar-03.html
https://lasallelalaguna.es/ucl/oly-v-mar-04.html
https://lasallelalaguna.es/ucl/oly-v-mar-05.html
https://lasallelalaguna.es/ucl/oly-v-mar-06.html
https://lasallelalaguna.es/ucl/oly-v-mar-07.html
https://lasallelalaguna.es/ucl/oly-v-mar-08.html
https://lasallelalaguna.es/ucl/oly-v-mar-09.html
https://www.atca.org/ucl/rexx/oly-v-mar-01.html
https://www.atca.org/ucl/rexx/oly-v-mar-02.html
https://www.atca.org/ucl/rexx/oly-v-mar-03.html
https://www.atca.org/ucl/rexx/oly-v-mar-04.html
https://www.atca.org/ucl/rexx/oly-v-mar-05.html
https://www.atca.org/ucl/rexx/oly-v-mar-06.html
https://www.atca.org/ucl/rexx/oly-v-mar-07.html
https://www.atca.org/ucl/rexx/oly-v-mar-08.html
https://www.atca.org/ucl/rexx/oly-v-mar-09.html
http://rivista.clamerinforma.it/ucl/cast/oly-v-mar-01.html
http://rivista.clamerinforma.it/ucl/cast/oly-v-mar-02.html
http://rivista.clamerinforma.it/ucl/cast/oly-v-mar-03.html
http://rivista.clamerinforma.it/ucl/cast/oly-v-mar-04.html
http://rivista.clamerinforma.it/ucl/cast/oly-v-mar-05.html
http://rivista.clamerinforma.it/ucl/cast/oly-v-mar-06.html
http://rivista.clamerinforma.it/ucl/cast/oly-v-mar-07.html
http://rivista.clamerinforma.it/ucl/cast/oly-v-mar-08.html
http://rivista.clamerinforma.it/ucl/cast/oly-v-mar-09.html
https://mrdeals.it/ucl/oly-v-mar-01.html
https://mrdeals.it/ucl/oly-v-mar-02.html
https://mrdeals.it/ucl/oly-v-mar-03.html
https://mrdeals.it/ucl/oly-v-mar-04.html
https://mrdeals.it/ucl/oly-v-mar-05.html
https://mrdeals.it/ucl/oly-v-mar-06.html
https://mrdeals.it/ucl/oly-v-mar-07.html
https://mrdeals.it/ucl/oly-v-mar-08.html
https://mrdeals.it/ucl/oly-v-mar-09.html
http://campusnews.uni-trier.de/ucl/oly-v-mar-01.html
http://campusnews.uni-trier.de/ucl/oly-v-mar-02.html
http://campusnews.uni-trier.de/ucl/oly-v-mar-03.html
http://campusnews.uni-trier.de/ucl/oly-v-mar-04.html
http://campusnews.uni-trier.de/ucl/oly-v-mar-05.html
http://campusnews.uni-trier.de/ucl/oly-v-mar-06.html
http://campusnews.uni-trier.de/ucl/oly-v-mar-07.html
http://campusnews.uni-trier.de/ucl/oly-v-mar-08.html
http://campusnews.uni-trier.de/ucl/oly-v-mar-09.html
http://www.skylineoffices.co.uk/cnn/oly-v-mar-01.html
http://www.skylineoffices.co.uk/cnn/oly-v-mar-02.html
http://www.skylineoffices.co.uk/cnn/oly-v-mar-03.html
http://www.skylineoffices.co.uk/cnn/oly-v-mar-04.html
http://www.skylineoffices.co.uk/cnn/oly-v-mar-05.html
http://www.skylineoffices.co.uk/cnn/oly-v-mar-06.html
http://www.skylineoffices.co.uk/cnn/oly-v-mar-07.html
http://www.skylineoffices.co.uk/cnn/oly-v-mar-08.html
http://www.skylineoffices.co.uk/cnn/oly-v-mar-09.html
The regulator must approve a vaccine as safe and effective before it can be administered to Canadians. Health Canada is currently evaluating vaccine candidates from U.S. pharmaceutical giant Pfizer and its German partner BioNTech, from U.S. biotechnology company Moderna, and from British pharmaceutical firm AstraZeneca.

Canadians anxiously await vaccine approval
The question of when a vaccine will be approved and distributed has become the subject of intense speculation and debate in Canada, as other countries like the U.S., U.K. and Germany have announced plans to begin distributing their vaccines in December.

Opposition politicians, some premiers and public health experts have criticized the Liberal government for falling behind other countries when it comes to approving vaccines and planning for their distribution.

Despite the criticism, none of those countries has granted final approval for a vaccine as of yet.

A closer look at the vaccines Canada is betting on to stem the spread of COVID-19
Canada ‘not at the back of the line’ for COVID-19 vaccine, Moderna chairman says
The U.S. Food and Drug Administration has scheduled a meeting for Dec. 10, during which independent public health experts will discuss whether to grant emergency-use approval to Pfizer’s vaccine. Moderna’s vaccine will be considered at a similar meeting one week after that.

At a technical briefing with reporters last week, Health Canada’s chief medical adviser said approval of the first COVID-19 vaccine in Canada could come within weeks.

Premiers want answers on vaccine delivery
In total, the federal government has secured agreements with seven companies for up to 429 million doses — the most per capita of any country in the world, according to research from Duke University’s Global Health Institute. Officials have said an estimated six million doses could arrive in the first three months of 2021.

But officials have provided little detail on exactly when those doses will arrive or how they will be distributed.

On Monday, Ontario Premier Doug Ford said he isn’t satisfied with the lack of information coming from the federal government and called on the prime minister to specify a delivery date for the province’s share of vaccines, adding that “the clock is ticking.”

Ford said he would speak directly to Pfizer on Monday afternoon to ask for details, but expected to be told the information must come from Ottawa.

Conservative Leader Erin O’Toole said the Liberals’ inability to specify a delivery timeline showed an “absence of leadership.”

Prime Minister Justin Trudeau has defended his government’s procurement plan, arguing that Canada has secured access to a wide variety of potential vaccines that provide the country with multiple options.

LISTEN | Prime Minsiter Justin Trudeau speaks to Matt Galloway on CBC Radio’s The Current

The Current13:17
Justin Trudeau on the cost of fighting the pandemic
After yesterday’s fiscal update, Prime Minister Justin Trudeau joins Matt Galloway to discuss the cost of fighting COVID-19, and how his government plans to roll out the vaccines that could finally subdue the pandemic. 13:17
“Everyone wants to know when this is going to be over,” Trudeau told CBC Radio’s The Current today. “What Canadians can know is we have the plan necessary to get through this, to get the vaccines here, to get the vaccines into people’s arms, and we’re going to do it with the provinces who have a high degree of expertise on this.”

Trudeau said Health Canada is working with the same data as regulators in the U.S., but that Canada will make its own decision on when and if to approve a vaccine.

“It is so important that these vaccines be safe for Canadians and we’re not going to cut any corners on making sure that, when Health Canada gives the thumbs up, that this vaccine is safe to go and to release into the population, [that] people can know that it will indeed be safe,” Trudeau said.

Last week, the federal government appointed Maj.-Gen. Dany Fortin, the current chief of staff to the Canadian Joint Operations Command and a former commander of the NATO mission in Iraq, to lead the national COVID-19 vaccine distribution effort.

With files from The Canadian Press and The Associated Press

CBC’s Journalistic Standards and Practices|About CBC News
Report Typo or Error
RELATED STORIES
Trudeau turns to the military to help with COVID-19 vaccine distribution
A closer look at the vaccines Canada is betting on to stem the spread of COVID-19
Red Cross chief calls for fight against ‘fake news’ about COVID-19 vaccine
Moderna to ask U.S., European regulators to OK emergency use of COVID-19 vaccine
As U.S., U.K. plan to roll out vaccines in December, Canada largely silent on distribution
Canada ‘not at the back of the line’ for COVID-19 vaccine, Moderna chairman says
Don’t want the COVID-19 vaccine? You could lose access to normal life, says U.K. minister
2nd big COVID-19 vaccine trial paused because of possible serious side-effect. Here’s what that means
Canada secures deals for up to 114M doses of potential COVID-19 vaccines from U.S. drug companies
Some companies will make big money off their COVID-19 vaccines — but not as much as they could

Written by

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store